2. Apoptosis
  3. Caspase
  4. Z-VAD(OMe)-FMK

Z-VAD(OMe)-FMK  (Synonyms: 氟甲基酮; Z-Val-Ala-Asp(OMe)-FMK)

目录号: HY-16658 纯度: ≥98.0%
COA 产品使用指南

摩尔计算器

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) 是一种不可逆的 pan-caspase 抑制剂。Z-VAD(OMe)-FMK 是泛素 C 末端水解酶 L1 (UCHL1) 抑制剂。Z-VAD(OMe)-FMK 通过靶向 UCHL1 活性位点对 UCHL1 进行不可逆地修饰。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Z-VAD(OMe)-FMK Chemical Structure

Z-VAD(OMe)-FMK Chemical Structure

CAS No. : 187389-52-2

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1748
In-stock
1 mg ￥650
In-stock
5 mg ￥1700
In-stock
10 mg ￥2700
In-stock
50 mg ￥5900
In-stock
100 mg   询价  
200 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Z-VAD(OMe)-FMK:

Z-VAD(OMe)-FMK 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 163 篇科研文献

WB

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: J Biol Chem. 2019 May 17;294(20):8161-8170.  [Abstract]

    HeLa cells are pretreated with or without the indicated concentrations of Z-VAD-FMK for 1 h before treatment with 3 μM T007-1 for 12, 24, or 48 h. Protein levels of cleaved PARP and caspase-3 are detected via western blot using GAPDH as a loading control.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Cell. 2018 Sep 6;174(6):1477-1491.e19.  [Abstract]

    WT and Tbk1-/-MEFs are pre-incubated with 20 μM zVAD-fmk in the presence or absence of Nec-1 s for 0.5 h and then stimulated with mTNFa for indicated periods of time. Complex II is isolated by anti-FADD immunoprecipitation and RIPK1 binding is revealed by immunoblotting.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Jan 18;9(2):27.  [Abstract]

    Overexpression PCDHGA9 induces GC cell apoptosis, cell cycle arrest, and autophagy. Western blot analysis determines that 10 μg/mL V-ZAD-FMK inhibits the activation of caspases.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: J Immunol. 2018 Jan 1;200(1):271-285.  [Abstract]

    RelA+/+ and RelA-/- MEFs are treated with TNF (20 ng/mL)/Smac Mimetics (10 nM) or TNF (20 ng/mL)/Smac Mimetics (10 nM)/Z-VAD (20 μM) at the indicated hours. Cell lysates are collected and subjected to western blot analysis using the indicated antibody.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Chem Res Toxicol. 2018 Dec 17;31(12):1418-1425.  [Abstract]

    HUVEC cells are stimulated with TCBQ for 6 h, pre-treated with either 10 μM Z-VADFMK (pan-caspase inhibitor) or 10 μM AC-YVAD-CHO (caspase 1/4/5 inhibitor) for 1 h. Then caspase 1/4/5 and GSDMD expressions are detected by Western blotting analysis.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Onco Targets Ther. 2018 Feb 26;11:1025-1035.  [Abstract]

    Reversine inhibits the expression levels of Cyclin A2, Cyclin B1, and p-Rb, but promotes p21 expression.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: PLoS One. 2018 Aug 6;13(8):e0201920.  [Abstract]

    The pretreatment of Z-VAD-FMK significantly reduces the levels of cleaved caspase-3 and cleaved PARP. The pretreatment of 3-MA blocks the conversion of LC3-I to LC3-II.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Cell Physiol Biochem. 2018;46(5):1779-1792.  [Abstract]

    Western blot and quantitative analysis of the expressions of ZO-1, Claudin-1, and Occludin. Apoptosis inhibitor Z-VAD(OMe)-FMK is used.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Cancer Lett. 2017 Feb 16;393:22-32.  [Abstract]

    Effects of p38 MAPK inhibitor (SB203580), ERK inhibitor (U0126), JNK inhibitor (SP600125), caspase inhibitor (Z-VAD-FMK) and NAC on SGC-7901 and MGC-803 treated with DOX/VCPA combination treatment. VCPA pretreatment strategy is the same as above. SB203580 (20 μM), U0126 (10 μM), SP600125 (20 μM), Z-VAD-FMK (10 μM) and NAC (5 mM) are treated 2 h before DOX (2 μg/mL) added into the culture, respectively. MAPK pathway protein levels are determined.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Elife. 2017 Dec 12;6:e30590.  [Abstract]

    Cultured S2 cells are treated with DMSO or z-VAD-FMK as indicated, and then mock infected for 24 hr or infected with DCV (MOI=5) for indicated time.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Biomed Pharmacother. 2017 Apr 5;90:446-454.  [Abstract]

    Caspase-8, Caspase-9, Caspase-3 and PARP cleavage levels are calculated by western blotting analysis in PC-3 cells treated under various conditions as indicated for 24 h. After ZVAD combination treatment, CHI-induced high expression of cleaved Caspase-8, Caspase-9, Caspase-3 and PARP is impeded dramatically.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Sci Rep. 2017 Jun 7;7(1):2929.  [Abstract]

    Caspase signaling pathway. MCF7 and MDA-MB-231 cells are pretreated with 10 µM Z-VAD-FMK and BOC-D-FMK for 1 h and then exposed to 80 μM ω3-FFAs and 20 μM ATRA for 48 h. The expression of PARP protein.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Sci Rep. 2016 Dec 1;6:38267.  [Abstract]

    SHK-induced splicing events that occurred in PARP, Caspase 8, 9 and 3 are also blocked by ZVAD-FMK. SHK-induced apoptosis is caspase-dependent in SGC-7901 gastric cancer cells. Detection of apoptosis-related protein PARP and caspase-3, -8, -9. GAPDH is used as a loading control.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Oncotarget. 2016 Dec 20;7(51):84810-84825.  [Abstract]

    Effect of proteasome or caspase inhibition on BCR/Abl protein suppression under oxygen or glucose shortage.K562 cells are incubated at 0.1% O2 in standard medium (top panels) or 21% O2 in the absence of glucose (bottom panels) for the indicated times, treated with the pan-caspase inhibitor z-VAD-fmk (50 μM) for the indicated times and lysed. BCR/Abl protein expression is determined by Western blotting using α-Tubulin as loading control.

    Z-VAD(OMe)-FMK purchased from MCE. Usage Cited in: Chinese Journal of Cell Biology. 2016, 38(10): 1232-1243.

    TNFα induces activation of caspase signaling pathway in L929-A cells but not L929-N cells.

    查看 Caspase 亚型特异性产品:

    查看所有亚型
    Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor[1]. Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1[2].

    IC50 & Target[1]

    Caspase

     

    体外研究
    (In Vitro)

    Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) 是一种广谱 caspase 抑制剂，已被证明能抑制 caspase 样蛋白酶的细胞内活化。注射 Z-VAD(OMe)-FMK 可抑制肺组织中的 caspase-3 活性，并显著减少末端 dUTP 缺口末端标记阳性细胞的数量[1]。浓度为 100 μM 的 Z-VAD(OMe)-FMK 可有效抑制 UCHL1 与血凝素标记的泛素乙烯基甲酯 (HA-UbVME) 的反应[2]。SAH 前 1 小时和 SAH 后 6 小时腹膜内注射 Z-VAD(OMe)-FMK。检查 caspase-3 的表达和阳性 TUNEL 作为细胞凋亡的标志物。 Z-VAD(OMe)-FMK 可抑制内皮细胞中的 TUNEL 和 caspase-3 染色，降低 caspase-3 活化，降低 BBB 通透性，缓解血管痉挛，消除脑水肿，改善神经系统结果[3]。Z-VAD(OMe)-FMK 是一种可渗透细胞的 caspase 抑制剂，可有效阻断由 SMN 缺乏引起的细胞死亡[4]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Z-VAD(OMe)-FMK 相关抗体:
    体内研究
    (In Vivo)

    注射 Z-VAD(OMe)-FMK（Z-Val-Ala-Asp(OMe)-FMK）后，小鼠的存活率显著延长。所有小鼠在 30 小时内死于 LPS。相比之下，接受 Z-VAD(OMe)-FMK 治疗的小鼠存活时间明显更长，27% 的小鼠存活时间超过 7 天[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    467.49

    Formula

    C22H30FN3O7
    CAS 号
    性状

    固体

    颜色

    White to off-white

    Sequence

    Z-Val-Ala-Asp(OMe)-FMK
    Sequence Shortening

    ZVA-D(OMe)-FMK
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式
    Powder -20°C 3 years
    In solvent -80°C 2 years
    -20°C 1 year
    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : 100 mg/mL (213.91 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 2.1391 mL 10.6954 mL 21.3908 mL
    5 mM 0.4278 mL 2.1391 mL 4.2782 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 5% DMSO    40% PEG300    5% Tween-80    50% Saline

      Solubility: ≥ 2.62 mg/mL (5.60 mM); 澄清溶液

    • 方案 二

      请依序添加每种溶剂： 5% DMSO    95% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.62 mg/mL (5.60 mM); 澄清溶液

    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 98.20%

    COA (192 KB) HNMR (199 KB) RP-HPLC (355 KB) LCMS (281 KB)

    产品使用指南 (1538 KB)
    参考文献
    Cell Assay
    [4]

    PCR products containing coding sequences for the dSMN (forward primer: 5′-TAA TAC GAC TCA CTA TAG GG AAG ACG TAC GAC GAG TCG-3′; and reverse primer: 5′-TAA TAC GAC TCA CTA TAG GG GTG GTG CTG GCT TCT TTC-3′; product length, 601bps; bold and italics letters represent T7 promoter sequences) and control Drosophila Presenilin (dPsn) gene (forward primer: 5′-TAA TAC GAC TCA CTA TAG GG TG GCT GCT GTC AAT CTC-3′; and reverse primer: 5′-TAA TAC GAC TCA CTA TAG GG CGA TAG CAA CGC TTC TTG-3′; product length: 543bps) are obtained and gel-purified. Double-stranded RNAs (dsRNA) are generated by transcription with Ribomax T7 Transcription kit and digested with Rnase-free DNase. The dsRNA products are ethanol precipitated and annealed by incubation at 65°C for 30 min and then slowly allowed to cool at room temperature. The annealed dsRNA products are analyzed on a 1% agaorse gel to ensure the majority of dsRNA existed as a single band. The dsRNA (2 μg) and/or plasmid DNAs (2 μg) are introduced into cells by using Cellfectin. Caspase inhibition is achieved by using 50 μM of Z-VAD(OMe)-FMK in the culture medium[4].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1][3]

    Mice[1]
    Mice used in this study are 5- to 6-week-old (20 to 22 g) ICR males. Mice are injected with 30 mg/kg LPS from E. coli serotype O111:B4 through the tail vein. A single intravenous injection of Z-VAD(OMe)-FMK (0.25 mg) is made 15 minutes before LPS injection, followed by three intravenous injections of Z-VAD(OMe)-FMK (0.1 mg each) per hour. Control mice are injected with the same volume of 1% DMSO in sterile saline.
    Rats[3]
    Male Sprague-Dawley rats weighing 300 to 350 g are anesthetized with α-chloralose (40 mg/kg IP) and urethane (400 mg/kg IP). Animals are intubated, and respiration is maintained with a small animal respirator. Rectal temperature is maintained at 37±0.5°C with a heating pad. The left external carotid artery is isolated and a 4.0 monofilament nylon suture is inserted through the internal carotid artery to perforate the middle cerebral artery. SAH is confirmed at autopsy in each rat. Sham-operated rats underwent the same procedures except that the suture is withdrawn after resistance is felt. Z-VAD(OMe)-FMK (50 μM per 0.3 mL) is injected intraperitoneally at 1 hour before and 6 hours after SAH induction. In vehicle group, rats underwent SAH induction and are treated with the same volume of vehicle (DMSO diluted in physiological buffer solution). No treatment is applied in sham-operated animals.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    Z-VAD(OMe)-FMK 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.1391 mL 10.6954 mL 21.3908 mL 53.4771 mL
    5 mM 0.4278 mL 2.1391 mL 4.2782 mL 10.6954 mL
    10 mM 0.2139 mL 1.0695 mL 2.1391 mL 5.3477 mL
    15 mM 0.1426 mL 0.7130 mL 1.4261 mL 3.5651 mL
    20 mM 0.1070 mL 0.5348 mL 1.0695 mL 2.6739 mL
    25 mM 0.0856 mL 0.4278 mL 0.8556 mL 2.1391 mL
    30 mM 0.0713 mL 0.3565 mL 0.7130 mL 1.7826 mL
    40 mM 0.0535 mL 0.2674 mL 0.5348 mL 1.3369 mL
    50 mM 0.0428 mL 0.2139 mL 0.4278 mL 1.0695 mL
    60 mM 0.0357 mL 0.1783 mL 0.3565 mL 0.8913 mL
    80 mM 0.0267 mL 0.1337 mL 0.2674 mL 0.6685 mL
    100 mM 0.0214 mL 0.1070 mL 0.2139 mL 0.5348 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Z-VAD(OMe)-FMK187389-52-2Z-Val-Ala-Asp(OMe)-FMKCaspaseInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Z-VAD(OMe)-FMK
    目录号：
    HY-16658
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z